Articles tagged with Autoantibodies
A new study suggests that preexisting autoantibodies in a small subset of the population can cause severe reactions to the live-attenuated Chikungunya vaccine. Researchers recommend screening people with these autoantibodies before vaccination, especially for those over age 65.
Researchers at The University of Osaka have identified a previously uncharacterized subset of immune cells called preTfr that play a critical role in preventing autoantibody production. In patients with severe COVID-19, these cells are significantly reduced, correlating with increased levels of harmful autoantibodies.
A new study by Johns Hopkins Medicine researchers identifies anti-TFAM antibodies as a significant risk factor for thrombotic events in people with lupus. These antibodies attack an essential protein crucial for maintaining the health of mitochondria, leading to damage and increased risk of blood clots.
A study using cryo-electron microscopy revealed that autoantibodies in myasthenia gravis disrupt acetylcholine receptor function by blocking or activating the immune system's complement pathway. This knowledge helps explain treatment variability and offers a foundation for personalized therapies targeting specific antibody interactions.
Scientists from the University of Zurich created decoy molecules that bind to autoantibodies, preventing them from inhibiting type I interferons. This restoration restores antiviral effect on viruses like influenza, offering hope for treatment and reducing viral disease susceptibility.
New discoveries by NYU researchers find that impaired regulatory T cells are a key contributor to Sjögren's disease in both mice and humans. Calcium signaling also plays a crucial role in the development of the autoimmune disorder, which affects glands producing saliva and tears.
Researchers developed a new diagnostic tool called FlowBEAT to measure antibodies in nasal cavities, finding that more than 70% of people with mild or moderate COVID-19 develop protective autoantibodies in the nose. These autoantibodies may play a role in regulating the immune system and preventing excessive inflammation.
A recent study found a correlation between higher anti-PD-1 autoantibody levels and lower survival rates in patients with advanced liver cancer, suggesting these autoantibodies as potential biomarkers for predicting treatment response. The discovery aims to improve treatment regimens for patients with liver cancer.
A team of researchers from Columbia University and Harvard University report that autoantibodies alone directly affect heart function in lupus patients. The study identified four autoantibodies that may directly affect the heart muscle, potentially leading to new therapeutic strategies.
A Berlin-led research team has discovered that a small population of immune cells called innate lymphoid cells (ILCs) trigger severe kidney inflammation in patients with lupus. ILCs, which are present in the kidneys, amplify organ damage when activated by NKp46 receptors.
A new method for detecting pancreatic cancer has been introduced using glycopeptide probes that selectively detect specific antibodies in blood samples. These probes mimic tumor-associated antigens and show promise for early detection screenings.
Researchers found that children's immune systems attacked their own tissues after latching onto a coronavirus protein resembling one found in multiple organs. Early intervention was crucial to prevent death in these cases, and the study has implications for understanding other autoimmune diseases.
The risk of developing type 1 diabetes (T1D) decreases in girls after age 10, while the risk in boys remains stable. Males with a single autoantibody have a significantly higher risk of T1D than their female counterparts.
A new study reveals that about two percent of the population develop autoantibodies against type 1 interferons, making them more susceptible to severe viral infections. The autoantibodies remain detectable in the blood for life and are associated with a compromised type 1 interferon system.
Researchers from Jilin University provide a comprehensive overview of brain injury biomarkers, including neuron-specific enolase, ubiquitin C-terminal hydrolase-L1, and neurofilament proteins. These biomarkers can help identify brain injuries and predict disease progression.
A study published in PNAS reveals that ETV5 enhances the expression of osteopontin, leading to the differentiation of T cells into follicular helper cells. In SLE patients, disease activity is proportional to ETV5 and osteopontin levels, suggesting a potential therapeutic target for treating lupus.
Researchers found auto-antibodies against type I interferons in severe and critical COVID-19 patients, compromising their immune response. This discovery highlights the importance of detecting these auto-antibodies in regular health checkups to better prepare for viral infections.
A groundbreaking study has uncovered a significant breakthrough in the diagnosis and monitoring of kidney diseases associated with nephrotic syndrome. Researchers identified anti-nephrin autoantibodies as a reliable biomarker for tracking disease progression, opening new avenues for personalized treatment approaches.
A team led by Massachusetts General Hospital used a new drug to save the life of a patient with immune thrombotic thrombocytopenic purpura (iTTP), a rare disorder characterized by uncontrolled clotting. The drug, recombinant ADAMTS13, reversed the disease process in a patient with an extremely severe form of iTTP.
A new study aims to investigate whether vaccination against SARS-CoV-2 can protect children at increased genetic risk of developing type 1 diabetes. The AVAnT1A Study, the largest intervention study to date, examines the relationship between viral infections and early childhood development.
Researchers have identified CAR-T cell therapy as a potential treatment for autoimmune diseases such as rheumatoid arthritis, SLE, and type 1 Diabetes Mellitus. Early studies have shown promising results in reducing disease activity and improving patients' quality of life, but long-term data on safety and efficacy is limited.
Scientists have identified a consistent signature of multiple sclerosis in the blood of patients years before they develop symptoms. The discovery, published in Nature Medicine, could lead to earlier diagnosis and treatment of the disease, affecting nearly 1 million people in the US.
A new murine model of dermatomyositis reveals the underlying immune system involvement in this highly progressive disease. The study identifies key components of the immune system responsible for disease development and suggests potential treatments targeting interleukin-6.
A study published in JCI Insight reveals that an unexpected mechanism is responsible for the loss of kidney cells' ability to filter toxins from blood in primary membranous nephropathy. The researchers found that signaling in the C3a/C3aR pathway plays a critical role in disease progression.
Researchers at DZNE and Charité developed a novel treatment for autoimmune encephalitis by reprogramming white blood cells to target misdirected antibodies. The new therapy, called CAAR-T cells, has shown accuracy in laboratory studies and is planned for clinical trials.
Research suggests that universal screening for type 1 diabetes at two ages could predict most cases of T1D by age 15. Dr. Emily K. Sims emphasizes the importance of identifying individuals with early, presymptomatic stages of disease to prevent life-threatening episodes and improve outcomes.
Researchers found novel autoantibodies implicated in hypertensive disorders of pregnancy, fetal growth restriction, and recurrent pregnancy loss. These autoantibodies are also associated with infertility and endometriosis-associated infertility.
The new Clinical Research Unit will investigate autoantibodies' role in neurological disorders, focusing on diagnosis and treatment. Researchers expect innovative therapies for patients with previously suspected diseases.
Researchers identify altered proteins predicting islet autoimmunity, a precursor to Type 1 diabetes. The findings mark an important step forward in predicting the disease months before symptoms appear.
A study published in Brain Behavior and Immunity found autoantibodies against a synaptic adhesion protein, neurexin 1α, in patients with schizophrenia. In mice, these autoantibodies caused schizophrenia-related changes, including reduced social behavior and cognitive function.
A new study published in Science Advances has found that certain antibodies against the Epstein-Barr virus can mistakenly target the brain and spinal cord, causing damage in multiple sclerosis patients. The research reveals a potential link between EBV infection and MS, with implications for personalized therapies.
Scientists have found that antibodies targeting βII-spectrin on mesangial cells are the trigger for IgA nephropathy. This discovery enables blood-based diagnosis and may lead to improved treatments.
Researchers at Linköping University found that C-reactive protein has a beneficial function in systemic lupus erythematosus, reducing interferon activity and promoting milder disease. The study's findings suggest new treatment strategies to reduce immune complexes and elevated interferon levels.
Researchers have identified a new class of 'good autoantibodies' that neutralize chemokines, reducing inflammation and promoting a favorable disease course in patients with long Covid. The discovery is linked to a lower risk of prolonged symptoms and a milder illness.
Researchers identified a type of immune cell called age-associated B cells as key drivers of lupus disease. Targeting these cells in a mouse model reduced disease progression, suggesting a potential new therapy for lupus patients.
Researchers at Osaka University found that male patients with COVID-19 have a faster loss of circulating Treg cells, leading to dysregulated antibody responses. Females, on the other hand, have higher levels of these cells, which may help protect them from infection.
A study found that antibodies to common antibiotic gentamicin are associated with an increased risk of progression to type 1 diabetes in children already genetically at risk. The researchers also identified an association between the FUT2 gene and the production of these antibodies, which may be compounding risks for type 1 diabetes.
Idiopathic plasmacytic lymphadenopathy (IPL) has been confirmed as a distinct clinicopathologically uniform disease, which can be reclassified into an independent subtype of idiopathic multicentric Castleman disease (iMCD). IPL showed greater plasmacytosis and hyperplastic germinal centers compared to non-IPL groups.
A study published in the European Respiratory Journal found that blood samples from long COVID patients show signs of autoimmune disease a year after infection. Nearly 80% of patients had autoantibodies in their blood, which persisted in around 30% of cases.
Osaka University researchers identified medullary thymic epithelial cells (mTECs) expressing neuromuscular molecules in myasthenia gravis-thymoma samples. These findings suggest a new connection between the two diseases and may lead to novel therapeutic methods.
Studies by UC Davis MIND Institute found predictive protein patterns in expecting mothers' blood and links between maternal autoantibodies and higher autistic traits. MAR ASD patterns were associated with autism before birth, with certain patterns predicting autism in previously diagnosed children.
Researchers from Arizona State University investigate autoantibodies in healthy individuals, revealing their pervasiveness and role in human health and disease. The findings aim to improve diagnostics and therapeutics for a range of illnesses.
Scientists have identified a potential new test for diagnosing Lyme disease by detecting autoantibodies to phospholipids. This approach could help clinicians diagnose the disease sooner and determine efficacy of treatments. The researchers' discovery has the potential to identify patients with persistent symptoms after treatment, makin...
Researchers discovered a viral infection can trigger autoimmunity in mice by disrupting the thymus's screening process for self-destructive T cells. Infection with murine roseolovirus led to autoimmune gastritis months later, highlighting a previously unknown way viruses can trigger autoimmunity.
Researchers found higher-than-expected levels of antiphospholipid autoantibodies in COVID-19 patients, causing endothelial cell activation and promoting clotting. Removing these antibodies from blood samples lost the activation effect, suggesting a potential cause of severe COVID-19 symptoms.
Researchers have identified several factors that can predict the development of long COVID, including the presence of certain autoantibodies, pre-existing Type 2 diabetes, and low cortisol levels. The study found that administering antivirals early in the disease course may also prevent some long COVID symptoms.
Researchers found that people infected with COVID-19 develop a wide variety of autoantibodies up to six months after recovery, and these autoantibodies persist over time. The study suggests that understanding these autoantibody responses could help identify ways to treat and prevent long-term symptoms.
The study analyzed data from 8,502 genetically high-risk children and found that half developed type 1 diabetes before age 6, while the other half developed it between ages 6 and 12. The findings suggest a different form of type 1 diabetes emerges in children as they grow older.
A new study reveals that COVID toes symptoms are caused by an immune response involving high levels of autoantibodies and type I interferon. Endothelial cells also play a crucial role in the development of the condition, according to the research published in the British Journal of Dermatology.
A growing body of studies suggests COVID-19 emulates systemic autoimmune disorders. Researchers analyzed serum from over 300 hospitalized patients, discovering a novel autoantibody that shields toxic NETs from destruction. Those with higher levels were more likely to develop severe symptoms.
The University of South Florida has been awarded a four-year, $69.9 million NIH grant to continue its Type 1 Diabetes Research study. The study aims to identify environmental factors that influence autoimmune destruction of beta cells in young children with genetic susceptibility to type 1 diabetes.
Researchers found that antiphospholipid antibodies bind to a specific complex in the body, triggering an autoimmune response that can lead to severe inflammation and organ damage. The study suggests that immunomodulatory therapies used for autoimmune diseases like SLE may also be effective in treating COVID-19.
Researchers developed a predictive model to monitor infant gene expression changes, potentially identifying early markers for T1D progression. The study used data from the Environmental Determinants of Diabetes in the Young (TEDDY) consortium and identified specific gene expression patterns related to natural killer cells.
A University of Birmingham-led study found that many COVID-19 patients produce immune responses against their own tissues or organs, including skin, skeletal muscle, and cardiac antibodies. The study suggests that these autoantibodies may contribute to the long-term consequences of SARS-CoV-2 infection.
A 23-year study found strong links between gestational diabetes during pregnancy and the development of type-1 and type-2 diabetes later in life. Women who experienced gestational diabetes were more prone to developing these conditions, highlighting the importance of autoantibody testing for risk assessment.
Researchers at Yale University found that autoantibodies in severe COVID-19 cases can attack healthy tissue and organs, leading to increased disease severity. The study also suggests that long-lived rogue antibodies may contribute to lasting medical symptoms, or long COVID cases.
Researchers used a mouse model to identify the role of autoreactive T cells against transcriptional intermediary factor 1γ (TIF1γ) in dermatomyositis. The study found that autoreactive CD8+ T cells contribute to the pathogenesis of the disease, while autoantibodies are non-pathogenic clinical markers.
Recent studies suggest that postural orthostatic tachycardia syndrome (POTS) is an autoimmune disorder characterized by elevated inflammatory markers and autoantibodies. Researchers have documented significant elevations of five inflammatory markers in patients with POTS, similar to those seen in other autoimmune disorders.
A study published in Molecular Psychiatry has identified patterns of maternal autoantibodies associated with autism spectrum disorder, allowing for early diagnosis and potential behavioral intervention. Researchers found that these biomarkers can predict the likelihood and severity of autism with high accuracy.
Researchers identified two novel genetic variants in the Siglec-10 protein that predispose individuals to polyneuropathy after gut infection. These variants impair the protein's ability to bind gangliosides, leading to autoantibody production and damage to neurons.